Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to evaluate the dose response, dose interval, efficacy, and safety of GSK961081 by studying three QD doses (100mcg, 400mcg and 800mcg) and three BID doses (100mcg, 200mcg and 400mcg) and salmeterol (50mcg) BID compared with placebo delivered by DISKUS in subjects with COPD.
Critère d'inclusion
- Chronic Obstructive Pulmonary Disease